In brief: MediVac, C3, Premier Bionics
Thursday, 20 October, 2005
Bob Atwill will join MediVac (ASX:MDV) as a consultant to assist in the commercialisation of the company's MetaMizer series II. Atwill was formerly sales and marketing director of London Stock Exchange listed orthopaedic company Corin Group.
Clinical Cell Culture (ASX:CCE, C3) has appointed distributors for its autologous cell harvesting device ReCell in Chile and Brazil, having secured market approval in Chile and with regulatory approval in Brazil expected in the next 6 to 12 months. This follows ReCell's approval for sale in Argentina. The company expects US FDA approval for ReCell by December 31.
Premier Bionics< (ASX:PBI) has appointed London-based Duncan Clegg as a non-executive director. Clegg is the chairman of specialist materials manufacturer Low & Bonar, listed on the London stock exchange, and a former executive director of international merchant banking group Lazard Brothers & Co. He is also vice chairman of the Port of London Authority and a member of the Cook Society, which encourages business connections between Australia and the UK.
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
